WeissLaw LLP is investigating Kadmon Holdings, Inc.
NEW YORK, September 10, 2021 / PRNewswire / – WeissLaw LLP investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kadmon Holdings, Inc. (“Kadmon Holdings” or the “Company”) (NASDAQ: KDMN) in connection the proposed acquisition of the Company by Sanofi (âSanofiâ) (NASDAQ: SNY). Under the terms of the Merger Agreement, the shareholders of the Company will receive $ 9.50 per share in cash for each Kadmon Holdings common share they hold. The transaction is valued at approximately $ 1.9 billion.
If you have Kadmon Holdings shares and would like to discuss this survey or if you have any questions regarding this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
1500 Broadway, 16e Ground
new York, NY 10036
WeissLaw LLP is considering whether (i) the board of directors of Kadmon Holdings has acted in the best interests of the shareholders of the Company in accepting the proposed transaction, (ii) the $ 9.50 the merger consideration per share adequately remunerates the shareholders of Kadmon Holdings, and (iii) all information regarding the sale process and the valuation of the transaction will be fully and fairly disclosed. In particular, the merger consideration is lower than the $ 10.75 median of the price targets set by the analysts following the Company and at least one analyst has set a price target for the Company of $ 20.00 per share, $ 10.50 above the merger price per share.
WeissLaw LLP has litigated hundreds of class and derivative shareholder actions for breach of corporate and fiduciary obligations. We have recovered over $ 1 billion from defrauded clients and obtained significant corporate governance relief in many of these cases. If you have information or want legal advice regarding possible corporate wrongdoing (including insider trading, waste of company assets, accounting fraud or misleading information), fraud consumer (including misleading advertising, defective products, or other deceptive marketing practices), or violations of antitrust laws, please email us at [emailÂ protected]
SOURCE WeissLaw LLP